Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Restless Legs Syndrome
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign…
A strong advocate for women’s health and the first managing director of Roche Diagnostics India to be under 40…
With his over 25 years’ experience in running growing businesses and establishing start-ups, Ranjit Madan, CEO of…
Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the…
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role…